RPL7AP25

Across TCGA pan-cancer cohorts, RPL7AP25 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of RPL7AP25’s most consistent transcriptional readouts.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where RPL7AP25 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL7AP25 is over-expressed in tumor, although a few such as ESCA show the opposite, repressed pattern.

PRAD, ESCA, and LUSC are the cancer types where RPL7AP25 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL7AP25 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PRAD	All	All	+0.030	.046	2	view →
ESCA	Female	All	−0.076	.003	1	view →
LUSC	Male	II,III,IV	+0.030	.006	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

RPL7AP25–PRAD

Open the PRAD breakdown →